{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T04:04:16Z","timestamp":1749787456692,"version":"3.41.0"},"reference-count":32,"publisher":"BMJ","funder":[{"name":"South-Eastern Norway Regional Health Authority (Helse S\u00f8r-\u00d8st RHF), Grant","award":["900020"],"award-info":[{"award-number":["900020"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2025,6,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Subcutaneous (SC) administration is the preferred parenteral opioid route in palliative care, while intravenous infusion may allow faster titration. Comparative evidence remains limited. This study assessed whether intravenous or SC morphine, administered by continuous infusion with bolus doses, offered advantages in (1) time to stable infusion rate and (2) time to pain relief following a bolus dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this double-blind, double-dummy randomised controlled trial, 60 hospitalised palliative care patients with cancer requiring opioid rotation to parenteral morphine were randomised to continuous SC or intravenous infusion with bolus doses over 48 hours.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mean time to final infusion rate was 20.4 hours (95% CI: 15.2 to 25.6) for SC and 16.3 hours (95% CI: 10.5 to 22.2) for intravenous (mean difference: 4.1 hours, 95% CI: \u20133.6 to 11.7; p=0.293). Median time to effect from bolus doses was 20 min (Q1, Q3: 15, 23) for SC and 15 min (10, 20) for intravenous (HR=1.08, 95% CI: 0.61 to 1.88; p=0.795), indicating no significant difference. NRS scores decreased from 3.9 to 2.1 (SC) and 3.3 to 2.3 (intravenous). Infusion rates increased from 2.4 to 3.3 mg\/hour, bolus doses from 4.6 to 6.6 mg. Of 604 boluses, the proportion of effective doses was similar between groups. One intravenous patient developed catheter-related thrombosis and infection post-intervention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>No statistically significant or clinically meaningful differences in effectiveness or safety were observed between SC and intravenous morphine administration. Both routes allowed similar titration patterns, supporting the use of either route in palliative care without compromising analgesic efficacy or safety.<\/jats:p><\/jats:sec>","DOI":"10.1136\/spcare-2025-005593","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T08:45:14Z","timestamp":1749717914000},"page":"spcare-2025-005593","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Subcutaneous versus intravenous route switch from oral to parenteral morphine in patients with cancer: randomised controlled trial"],"prefix":"10.1136","clinical-trial-number":[{"clinical-trial-number":"nct05236647","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5264-0540","authenticated-orcid":false,"given":"Eva","family":"Gravdahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siri","family":"Steine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u016brat\u0117 \u0160altyt\u0117","family":"Benth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Knut Magne","family":"Augestad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0931-0027","authenticated-orcid":false,"given":"Olav Magnus","family":"Fredheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"2025061201450768000_spcare-2025-005593v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(87)80019-2"},{"key":"2025061201450768000_spcare-2025-005593v1.2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy152"},{"key":"2025061201450768000_spcare-2025-005593v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70040-2"},{"key":"2025061201450768000_spcare-2025-005593v1.4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10636"},{"key":"2025061201450768000_spcare-2025-005593v1.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.2008.01608.x"},{"key":"2025061201450768000_spcare-2025-005593v1.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0329-x"},{"key":"2025061201450768000_spcare-2025-005593v1.7","doi-asserted-by":"crossref","DOI":"10.1007\/s00520-024-08664-3","article-title":"Use of peripherally inserted central venous catheters and midline catheters for palliative care in patients with cancer: a systematic review","volume":"32","author":"Gravdahl","year":"2024","journal-title":"Support Care Cancer"},{"key":"2025061201450768000_spcare-2025-005593v1.8","doi-asserted-by":"crossref","DOI":"10.1007\/s00520-023-08045-2","article-title":"Use and safety of peripherally inserted central catheters and midline catheters in palliative care cancer patients: a retrospective review","volume":"31","author":"Gravdahl","year":"2023","journal-title":"Support Care Cancer"},{"key":"2025061201450768000_spcare-2025-005593v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(06)80006-0"},{"key":"2025061201450768000_spcare-2025-005593v1.10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00520-018-4368-x","article-title":"Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review","volume":"27","author":"Nijland","year":"2019","journal-title":"Support Care Cancer"},{"key":"2025061201450768000_spcare-2025-005593v1.11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/20494637221135835","article-title":"A systematic review of subcutaneous versus intramuscular or intravenous routes of opioid administration on pain outcomes in cancer and post-surgical clinical populations - challenging current assumptions in palliative care practice","volume":"17","author":"Fairbairn","year":"2023","journal-title":"Br J Pain"},{"key":"2025061201450768000_spcare-2025-005593v1.12","doi-asserted-by":"publisher","DOI":"10.1177\/0269216310383739"},{"key":"2025061201450768000_spcare-2025-005593v1.13","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aen103"},{"key":"2025061201450768000_spcare-2025-005593v1.14","doi-asserted-by":"crossref","unstructured":"Guy W . ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service, 1976.","DOI":"10.1037\/e591322011-001"},{"key":"2025061201450768000_spcare-2025-005593v1.15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"2025061201450768000_spcare-2025-005593v1.16","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.1998.16.3.1188","article-title":"Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ=C30 (+ 3)","volume":"16","author":"Hjermstad","year":"1998","journal-title":"J Clin Oncol"},{"key":"2025061201450768000_spcare-2025-005593v1.17","unstructured":"Scott NW , Fayers P , Aaronson NK , et al . EORTC QLQ-C30 reference values manual. 2008."},{"key":"2025061201450768000_spcare-2025-005593v1.18","doi-asserted-by":"crossref","DOI":"10.1186\/1472-684X-13-17","article-title":"The Richmond Agitation-Sedation Scale modified for palliative care inpatients (RASS-PAL): a pilot study exploring validity and feasibility in clinical practice","volume":"13","author":"Bush","year":"2014","journal-title":"BMC Palliat Care"},{"key":"2025061201450768000_spcare-2025-005593v1.19","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.annonc.2022.08.083","article-title":"An international, open-label, randomised trial comparing a two-step approach versus the standard three-step approach of the WHO analgesic ladder in patients with cancer","volume":"33","author":"Fallon","year":"2022","journal-title":"Ann Oncol"},{"key":"2025061201450768000_spcare-2025-005593v1.20","doi-asserted-by":"publisher","DOI":"10.1177\/0269216311406577"},{"key":"2025061201450768000_spcare-2025-005593v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)93401-T"},{"key":"2025061201450768000_spcare-2025-005593v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(96)00329-6"},{"key":"2025061201450768000_spcare-2025-005593v1.23","first-page":"27","article-title":"Continuous morphine infusions for cancer pain in resource-scarce environments: comparison of the subcutaneous and intravenous routes of administration","volume":"19","author":"Koshy","year":"2005","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2025061201450768000_spcare-2025-005593v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2009.03.009"},{"key":"2025061201450768000_spcare-2025-005593v1.25","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00141.x"},{"key":"2025061201450768000_spcare-2025-005593v1.26","doi-asserted-by":"publisher","DOI":"10.1191\/0269216303pm695oa"},{"key":"2025061201450768000_spcare-2025-005593v1.27","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2005.8.743"},{"key":"2025061201450768000_spcare-2025-005593v1.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-007-0352-6"},{"key":"2025061201450768000_spcare-2025-005593v1.29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ejpain.2009.06.009","article-title":"Rhythmic pattern of PCA opioid demand in adults with cancer pain","volume":"14","author":"Schiessl","year":"2010","journal-title":"Eur J Pain"},{"key":"2025061201450768000_spcare-2025-005593v1.30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jpainsymman.2010.11.020","article-title":"Patient-controlled analgesia in patients with advanced cancer. Should patients be in control?","volume":"42","author":"Dev","year":"2011","journal-title":"J Pain Symptom Manage"},{"key":"2025061201450768000_spcare-2025-005593v1.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.09.012"},{"key":"2025061201450768000_spcare-2025-005593v1.32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2478\/s11536-009-0032-7","article-title":"Reliability and validity of the EORTC QLQ-C30 in palliative care cancer patients","volume":"4","author":"Jocham","year":"2009","journal-title":"Open Med"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2025-005593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T08:45:18Z","timestamp":1749717918000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2025-005593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":32,"alternative-id":["10.1136\/spcare-2025-005593"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2025-005593","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]}}}